Zobrazeno 1 - 10
of 6 488
pro vyhledávání: '"CAR-T cell"'
Autor:
David Mao, Anne S. Reiner, Xi Chen, Jae Park, Martina Pennisi, Miguel-Angel Perales, Edward K. Avila, Bianca D. Santomasso
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Patients who develop chimeric antigen receptor (CAR) T-cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) frequently undergo evaluation with electroencephalography (EEG). We hypothesize that EEG features and Synek sc
Externí odkaz:
https://doaj.org/article/ec262d90bc1f4fecb5981ad4f7aba238
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance outcomes in patients afflicted with malignancies, particularly those enduring relapsed or refractory hematological mali
Externí odkaz:
https://doaj.org/article/792ff3c390cb4a2e97d09c5b64d8c7d1
Publikováno v:
Inflammation and Regeneration, Vol 44, Iss 1, Pp 1-19 (2024)
Abstract Since chimeric antigen receptor T (CAR-T) cells were introduced three decades ago, the treatment using these cells has led to outstanding outcomes, and at the moment, CAR-T cell therapy is a well-established mainstay for treating CD19 + mali
Externí odkaz:
https://doaj.org/article/055e55e00c6444ae9384f75cf83645e1
Autor:
Elisa Russo, Massimiliano Gambella, Anna Maria Raiola, Elena Beltrametti, Valentina Zanetti, Giuseppe Chirco, Francesca Viazzi, Emanuele Angelucci, Pasquale Esposito
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, yet it carries significant risks, including acute kidney injury (AKI). In this study, we investigated the risk factors and clinica
Externí odkaz:
https://doaj.org/article/6f8a1ee9b08b477eb92a55a9a8bf549b
Autor:
Kexin Ai, Bowen Liu, Xiaomei Chen, Chuxin Huang, liping Yang, Weiya Zhang, Jianyu Weng, Xin Du, Kongming Wu, Peilong Lai
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-29 (2024)
Abstract Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application in solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cy
Externí odkaz:
https://doaj.org/article/e9c3a324bf694c22927aea21e4a4bb88
Publikováno v:
Bezmiâlem Science, Vol 12, Iss 4, Pp 470-478 (2024)
Objective: Chimeric antigen receptor (CAR)-T cell therapy is a new immunotherapy approach that has started to been used in recent years and is developing rapidly. CAR-T cells, which are used as an immunotherapy treatment, destroy the tumor cell both
Externí odkaz:
https://doaj.org/article/315a3be6bc8a41409827051c74783e55
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We performed a systematic review and meta-analysis to evaluate the benefits of
Externí odkaz:
https://doaj.org/article/d37c34b1d0d149ea9f410408e3c3ceb8
Autor:
Prasanna Srinivasan Ramalingam, T. Premkumar, Vino Sundararajan, Md Sadique Hussain, Sivakumar Arumugam
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Mutant KRAS promotes the proliferation, metastasis, and aggressiveness of various cancers including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal adenocarcinoma (CRC) respectively. Mutant KRAS th
Externí odkaz:
https://doaj.org/article/b81ba153528748408459b77d85bb3ba4
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-19 (2024)
Abstract In recent years, immunotherapy has developed rapidly as a new field of tumour therapy. However, the efficacy of tumour immunotherapy is not satisfactory due to the immune evasion mechanism of tumour cells, induction of immunosuppressive tumo
Externí odkaz:
https://doaj.org/article/c59c35806000402bb07f80262594176d
Autor:
Xiaoxi Zhou, Qiuxia Yu, Zigang Dai, Jue Wang, Chunrui Li, Liang Huang, Yicheng Zhang, Yang Cao
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Relapsed/refractory (R/R) primary and secondary central nervous system lymphomas (PCNSL, SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. We retrospectively compared the safety and
Externí odkaz:
https://doaj.org/article/07e8dc0d486f4f0ebba53ec5ac6f86fd